These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15756932)
1. Administration of myo-inositol plus ethanolamine elevates phosphatidylethanolamine plasmalogen in the rat cerebellum. Hoffman-Kuczynski B; Reo NV Neurochem Res; 2005 Jan; 30(1):47-60. PubMed ID: 15756932 [TBL] [Abstract][Full Text] [Related]
2. Studies of myo-inositol and plasmalogen metabolism in rat brain. Hoffman-Kuczynski B; Reo NV Neurochem Res; 2004 Apr; 29(4):843-55. PubMed ID: 15098950 [TBL] [Abstract][Full Text] [Related]
3. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Kuczynski B; Reo NV Neurochem Res; 2006 May; 31(5):639-56. PubMed ID: 16770735 [TBL] [Abstract][Full Text] [Related]
4. Influence of Myo-inositol Plus Ethanolamine on Plasmalogens and Cell Viability during Oxidative Stress. Sibomana I; Grobe N; DelRaso NJ; Reo NV Chem Res Toxicol; 2019 Feb; 32(2):265-284. PubMed ID: 30604967 [TBL] [Abstract][Full Text] [Related]
5. Serum Ethanolamine Plasmalogen and Urine Myo-Inositol as Cognitive Decline Markers. Maeba R; Araki A; Fujiwara Y Adv Clin Chem; 2018; 87():69-111. PubMed ID: 30342713 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Wood PL; Khan MA; Smith T; Ehrmantraut G; Jin W; Cui W; Braverman NE; Goodenowe DB Lipids Health Dis; 2011 Oct; 10():182. PubMed ID: 22008564 [TBL] [Abstract][Full Text] [Related]
8. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease. Wood PL; Smith T; Lane N; Khan MA; Ehrmantraut G; Goodenowe DB Lipids Health Dis; 2011 Dec; 10():227. PubMed ID: 22142382 [TBL] [Abstract][Full Text] [Related]
9. Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Mawatari S; Katafuchi T; Miake K; Fujino T Lipids Health Dis; 2012 Nov; 11():161. PubMed ID: 23170810 [TBL] [Abstract][Full Text] [Related]
10. Lymphatic absorption of choline plasmalogen is much higher than that of ethanolamine plasmalogen in rats. Nishimukai M; Yamashita M; Watanabe Y; Yamazaki Y; Nezu T; Maeba R; Hara H Eur J Nutr; 2011 Sep; 50(6):427-36. PubMed ID: 21152926 [TBL] [Abstract][Full Text] [Related]
11. Oral Administration of Ethanolamine Glycerophospholipid Containing a High Level of Plasmalogen Improves Memory Impairment in Amyloid β-Infused Rats. Yamashita S; Hashimoto M; Haque AM; Nakagawa K; Kinoshita M; Shido O; Miyazawa T Lipids; 2017 Jul; 52(7):575-585. PubMed ID: 28551706 [TBL] [Abstract][Full Text] [Related]
13. Serum ethanolamine plasmalogens improve detection of cognitive impairment among elderly with high excretion levels of urinary myo-inositol: A cross-sectional study. Maeba R; Araki A; Ishii K; Ogawa K; Tamura Y; Yasunaga M; Minami U; Komori A; Okazaki T; Nishimukai M; Hara H; Fujiwara Y Clin Chim Acta; 2016 Jan; 453():134-40. PubMed ID: 26680299 [TBL] [Abstract][Full Text] [Related]
14. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. Munn NJ; Arnio E; Liu D; Zoeller RA; Liscum L J Lipid Res; 2003 Jan; 44(1):182-92. PubMed ID: 12518037 [TBL] [Abstract][Full Text] [Related]
15. Plasmalogen mediates integration of adherens junction. Takahashi T; Honsho M; Abe Y; Fujiki Y J Biochem; 2019 Nov; 166(5):423-432. PubMed ID: 31236591 [TBL] [Abstract][Full Text] [Related]
16. Absorption Kinetics of Ethanolamine Plasmalogen and Its Hydrolysate in Mice. Yamashita S; Fujiwara K; Tominaga Y; Nguma E; Takahashi T; Otoki Y; Yamamoto A; Higuchi O; Nakagawa K; Kinoshita M; Miyazawa T J Oleo Sci; 2021 Feb; 70(2):263-273. PubMed ID: 33456005 [TBL] [Abstract][Full Text] [Related]
17. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors. Murphy CT; Bullock AJ; Lindley CJ; Mills SJ; Riley AM; Potter BV; Westwick J Mol Pharmacol; 1996 Nov; 50(5):1223-30. PubMed ID: 8913354 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of phosphatidylethanolamine and ethanolamine plasmalogen by the CDP-ethanolamine and decarboxylase pathways in rat heart, kidney and liver. Arthur G; Page L Biochem J; 1991 Jan; 273(Pt 1)(Pt 1):121-5. PubMed ID: 1989575 [TBL] [Abstract][Full Text] [Related]
19. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Grégoire L; Smith T; Senanayake V; Mochizuki A; Miville-Godbout E; Goodenowe D; Di Paolo T Behav Brain Res; 2015 Jun; 286():328-37. PubMed ID: 25771209 [TBL] [Abstract][Full Text] [Related]
20. Thyrotropin-releasing hormone reduces myo-inositol content in rat cerebellum pretreated with lithium. Miyamoto Y; Kikkawa R; Hatanaka I; Yasuda H; Terada M; Yamashita M; Shigeta Y J Neurochem; 1987 Jul; 49(1):88-91. PubMed ID: 3035101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]